**Supplementary Figure Legends**

**Supplementary Fig. 1. Kaplan-Meier analysis of Overall survival**

The median overall survival (OS) from the initiation of anti-PD-1/PD-L1 antibody therapy was 29.0 months in the patients with higher enhancement nodules on hepatobiliary phase, and 24.5 months in the HCC patients with hypointense nodules (p=0.523).

**Supplementary Fig. 2. The waterfall plots of maximum intrahepatic nodule response to anti-PD-1/PD-L1 antibody**

The tumor size was determined based on The Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).